Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Date:5/6/2008

cepharm.com" target="_new">http://www.cadencepharm.com.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements. Forward-looking statements include statements regarding: the timeframes in which Cadence expects to complete enrollment in, and announce the results of, clinical trials of its product candidates; the timeframes in which Cadence anticipates filing submissions with regulatory authorities seeking marketing authorizations for its product candidates; the expected impact of clinical trial results on the market and clinical value of Cadence's product candidates; and the potential for Cadence's product candidates to address unmet medical needs. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Cadence's business, including, without limitation: the outcomes of final analyses of data from Cadence's clinical trials of its product candidates may vary from the company's initial analyses, and the FDA may not agree with Cadence's interpretation of such results; the company's clinical trials may produce negative or inconclusive results, or may be inconsistent with previously conducted clinical trials; Cadence may experience delays in completing its clinical trials or achieving its product development goals, or experience problems with the designs or execution of its clinical trials; the company may decide, or be required by FDA, to expand or modify its ongoing clinical trials or conduct additional clinical trials in order to support applications for market approval of its product candidates; the market demand for Cadence's product candidates, and their ability to compete with new or existing products, may be less than anticipated; the company's product
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
3. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
4. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
5. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
6. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
7. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
8. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
9. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
11. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... (NYSE: RMD ), an innovator and pioneer ... and other chronic respiratory conditions, has won a permanent ... medical device manufacturer APEX Medical Corp. (APEX), prohibiting sales ... 220 masks.  The judgment was entered by the Regional ... appealable, and applies throughout Germany.  The ...
(Date:7/28/2014)... , July 28, 2014  ANI Pharmaceuticals, Inc. (NASDAQ: ... plans to release its second quarter and year-to-date 2014 ... opening of the U.S. financial markets. The earnings press ... of the Company,s website, www.anipharmaceuticals.com . ... Officer, and Charlotte C. Arnold , Vice President ...
(Date:7/28/2014)... , July 28, 2014  ProteinSimple announced today ... the Simple Western. This new assay allows users to detect ... first time, Simple Western users can analyze proteins without ... Simple Western has changed protein analysis as we know ... Western blot protocols - no messy gels, no transfer ...
Breaking Medicine Technology:ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results 2ProteinSimple Says "Never Run a Gel Again!" 2
... VioQuest,Pharmaceuticals (OTC Bulletin Board: VQPH) today ... of Lenocta(TM) (sodium stibogluconate), a novel,protein tyrosine ... immune stimulant approved for the treatment of ... cancers. The open-label Phase IIa study is,designed ...
... CuraGen Corporation,(Nasdaq: CRGN ), a clinical-stage biopharmaceutical ... Exchange: TOPO) announced,today that updated preliminary clinical trial ... T-cell lymphomas, and new preclinical data,evaluating belinostat on ... 2007 American Society of Hematology (ASH) 49th Annual ...
Cached Medicine Technology:VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor 2VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor 3VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor 4CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 2CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 3CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 4CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 5
(Date:7/28/2014)... Camp Soaring Eagle today announced it ... Cornville, AZ. The nonprofit organization, founded in July ... to attend medically supervised camps at no cost ... a variety of programs to Arizona families and ... illnesses including: Illness Specific Camping Weekends, Illness Specific ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 An estimated ... year from metastatic breast and prostate cancers – an ... cancer has spread to other parts of the body, ... researchers at Drexel University College of Medicine ... identified that inhibits metastatic progression by blocking tumor cells ...
(Date:7/28/2014)... A revised version of a surgical procedure to treat ... more than 90 percent of the time in patients ... the MGH Division of Plastic and Reconstructive Surgery report ... the non-endoscopic procedure all of whom had headaches ... symptom relief a year later. The team,s paper ...
(Date:7/28/2014)... Glutamine is the most abundant single amino ... conditionally essential during times when the body undergoes large ... Immune System Support. , Having a heavy work out ... with additional glutamine may be advantageous. Glutamine supplementation may ... digestion and immune system function. Stress on the body ...
(Date:7/28/2014)... (HealthDay News) --,The more chronic medical conditions people have ... be, a new study claims. Since nearly ... scientists at Johns Hopkins Bloomberg School of Public Health ... gains in life expectancy are slowing in the United ... diabetes, kidney disease and heart failure is now the ...
Breaking Medicine News(10 mins):Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2
... as the newest participants in the Hartford Doctoral Fellows ... by the John A. Hartford Foundation , administered by ... James Lubben , DSW, MPH. Each fellow receives ... his or her home institution, which enables the recipient to ...
... , FRIDAY, Oct. 28 (HealthDay News) -- ... improvement if they,re placed in a classroom with higher-achieving ... low-achievers, researchers say. The findings are important because ... to poor children, whose development of language skills may ...
... recently awarded $7.2 million for the competitive renewal of ... Cancer Center,s Daniel Sullivan, M.D., executive vice president and ... through September 2016. The SEP2C enrolls patients to ... across six member sites. Moffitt is the lead site ...
... shrinking population of trim Americans against an expanding population of ... "fat bans." These "fat policies" would be designed to ... the growth in Americans, waistlines and in the country,s healthcare ... the Land of the Free and the Home of ...
... takes advantage of ovarian cancer,s reliance on folate appears to ... effects, researchers say., The therapy uses the folate receptors on ... a substance attracted to the receptors with a chemotherapeutic agent ... Chief of the Section of Gynecologic Oncology at Georgia Health ...
... burn up to 120 calories in half an hour while wheeling ... as much as someone doing the same action in a motorized ... and as much as 258 calories while fencing in a 30-minute ... This is according to a review article written by Professor David ...
Cached Medicine News:Health News:Prestigious Hartford grants bolster awardees' social work research 2Health News:Prestigious Hartford grants bolster awardees' social work research 3Health News:Preschool Peers May Boost Language Skills in Kids 2Health News:Home of the free - land of the fat? 2Health News:Folate receptors may serve as a front door to ovarian cancer treatment 2Health News:UT study looks at manual wheelchair use, exercise and calorie burning 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: